Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

97 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Reduced-intensity conditioning with fludarabine and busulfan versus fludarabine and melphalan for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
Baron F, Labopin M, Peniket A, Jindra P, Afanasyev B, Sanz MA, Deconinck E, Nagler A, Mohty M. Baron F, et al. Among authors: peniket a. Cancer. 2015 Apr 1;121(7):1048-55. doi: 10.1002/cncr.29163. Epub 2014 Nov 25. Cancer. 2015. PMID: 25424330 Free article.
Allogeneic haematopoietic stem cell transplant in patients with lower risk myelodysplastic syndrome: a retrospective analysis on behalf of the Chronic Malignancy Working Party of the EBMT.
Robin M, Porcher R, Zinke-Cerwenka W, van Biezen A, Volin L, Mufti G, Craddock C, Finke J, Richard C, Passweg J, Peniket A, Maertens J, Sucak G, Gedde-Dahl T, Vitek A, Nagler A, Blaise D, Beelen D, Maillard N, Schwerdtfeger R, de Witte T, Kroger N. Robin M, et al. Among authors: peniket a. Bone Marrow Transplant. 2017 Feb;52(2):209-215. doi: 10.1038/bmt.2016.266. Epub 2016 Nov 7. Bone Marrow Transplant. 2017. PMID: 27819688
Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia.
Tauro S, Craddock C, Peggs K, Begum G, Mahendra P, Cook G, Marsh J, Milligan D, Goldstone A, Hunter A, Khwaja A, Chopra R, Littlewood T, Peniket A, Parker A, Jackson G, Hale G, Cook M, Russell N, Mackinnon S. Tauro S, et al. Among authors: peniket a. J Clin Oncol. 2005 Dec 20;23(36):9387-93. doi: 10.1200/JCO.2005.02.0057. Epub 2005 Nov 28. J Clin Oncol. 2005. PMID: 16314618 Clinical Trial.
Validation of the revised IPSS at transplant in patients with myelodysplastic syndrome/transformed acute myelogenous leukemia receiving allogeneic stem cell transplantation: a retrospective analysis of the EBMT chronic malignancies working party.
Scheid C, de Wreede L, van Biezen A, Koenecke C, Göhring G, Volin L, Maertens J, Finke J, Passweg J, Beelen D, Cornelissen JJ, Itälä-Remes M, Chevallier P, Russell N, Petersen E, Milpied N, Richard Espiga C, Peniket A, Sierra J, Mufti G, Crawley C, Veelken JH, Ljungman P, Cahn JY, Alessandrino EP, de Witte T, Robin M, Kröger N. Scheid C, et al. Among authors: peniket a. Bone Marrow Transplant. 2017 Nov;52(11):1519-1525. doi: 10.1038/bmt.2017.171. Epub 2017 Sep 11. Bone Marrow Transplant. 2017. PMID: 28892084 Free PMC article.
Favourable outcome for patients with myeloid disorders treated with fludarabine-melphalan reduced-intensity conditioning and allogeneic bone marrow stem cell transplantation without the use of T-lymphocyte-depleting antibodies.
Malladi RK, Peniket AJ, Norton AE, Campbell AJ, Collins GP, Samol J, Eagleton H, Miller E, Morgenstern G, Jones J, Keen-Mcguire A, Barnardo M, Littlewood TJ. Malladi RK, et al. Among authors: peniket aj. Eur J Haematol. 2004 Aug;73(2):85-92. doi: 10.1111/j.1600-0609.2004.00266.x. Eur J Haematol. 2004. PMID: 15245506 Clinical Trial.
Systematic Review of Patient-Reported Outcome Measures in Graft-versus-Host Disease.
Kilgour JM, Wali G, Gibbons E, Scherwath A, Barata Badiella A, Peniket A, Schoemans H, Matin RN; cGVHD Eurograft Network. Kilgour JM, et al. Among authors: peniket a. Biol Blood Marrow Transplant. 2020 May;26(5):e113-e127. doi: 10.1016/j.bbmt.2020.01.022. Epub 2020 Feb 3. Biol Blood Marrow Transplant. 2020. PMID: 32028026 Free article. Review.
Factors predicting long-term survival after T-cell depleted reduced intensity allogeneic stem cell transplantation for acute myeloid leukemia.
Craddock C, Nagra S, Peniket A, Brookes C, Buckley L, Nikolousis E, Duncan N, Tauro S, Yin J, Liakopoulou E, Kottaridis P, Snowden J, Milligan D, Cook G, Tholouli E, Littlewood T, Peggs K, Vyas P, Clark F, Cook M, Mackinnon S, Russell N. Craddock C, et al. Among authors: peniket a. Haematologica. 2010 Jun;95(6):989-95. doi: 10.3324/haematol.2009.013920. Epub 2009 Nov 30. Haematologica. 2010. PMID: 19951968 Free PMC article.
Augmented Reduced-Intensity Regimen Does Not Improve Postallogeneic Transplant Outcomes in Acute Myeloid Leukemia.
Craddock C, Jackson A, Loke J, Siddique S, Hodgkinson A, Mason J, Andrew G, Nagra S, Malladi R, Peniket A, Gilleece M, Salim R, Tholouli E, Potter V, Crawley C, Wheatley K, Protheroe R, Vyas P, Hunter A, Parker A, Wilson K, Pavlu J, Byrne J, Dillon R, Khan N, McCarthy N, Freeman SD. Craddock C, et al. Among authors: peniket a. J Clin Oncol. 2021 Mar 1;39(7):768-778. doi: 10.1200/JCO.20.02308. Epub 2020 Dec 29. J Clin Oncol. 2021. PMID: 33373276 Free PMC article. Clinical Trial.
A multicenter comparative acute myeloid leukemia study: can we explain the differences in the outcomes in resource-constrained settings?
Silveira DRA, Coelho-Silva JL, Silva WF, Vallance G, Pereira-Martins DA, Madeira MIA, Figueredo-Pontes LL, Velloso EDRP, Simões BP, Peniket A, Danby R, Rego EM, Vyas P, Traina F, Bendit I, Quek L, Rocha V. Silveira DRA, et al. Among authors: peniket a. Leuk Lymphoma. 2021 Jan;62(1):147-157. doi: 10.1080/10428194.2020.1827252. Epub 2020 Sep 30. Leuk Lymphoma. 2021. PMID: 32996373
97 results